Kevin Peng
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Kevin Peng has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
- Samir Mitragotri
Harvard John A. Paulson School of Engineering and Applied Sciences Harvard University Allston Massachusetts USA
2 shared publications - Zongmin Zhao
Department of Pharmaceutical Sciences University of Illinois Chicago Chicago Illinois USA
2 shared publications Anna Mandinova
Cutaneous Biology Research Center, Massachusetts General Hospital and Harvard Medical School, Building 149 13th Street, Charlestown, MA 02129, USA
1 shared publicationAnusha Pusuluri
School of Engineering and Applied Sciences, Harvard University, Cambridge, MA 02138, USA
1 shared publication- Apoorva Sarode
Synthetic Molecule Pharmaceutical Sciences, Genentech, Inc., South San Francisco, California 94080, United States
1 shared publication - Brittney Sell
Department of Tumor Metastasis and Microenvironment, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida. 6
1 shared publication
Latest Publications
- Open Access
- 11 June 2021
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 7 (24) , eabe6627
Hyaluronic acid conjugates for topical treatment of skin cancer lesions
Polymer-drug conjugates are developed for the topical ratiometric delivery of a synergistic drug pair to treat skin cancers.
- 11 June 2021
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 7 (24) , eabe6627
Open AccessHyaluronic acid conjugates for topical treatment of skin cancer lesions
Polymer-drug conjugates are developed for the topical ratiometric delivery of a synergistic drug pair to treat skin cancers.
- 17 November 2020
- Published by Wiley in Advanced Healthcare Materials
- Vol. 10 (2) , e2001455
Enhancement of Anticancer Efficacy and Tumor Penetration of Sorafenib by Ionic Liquids
Ionic liquids (ILs) possess unique solvation and biological properties for drug delivery. Choline and geranic acid (CAGE) in particular, has been successfully formulated to orally deliver insulin and hydrophobic therapeutics such as sorafenib (SRF). However, relatively little is known about the effect of CAGE on intracellular delivery of drugs. Here the effect of low‐concentration CAGE (−1) on the delivery of SRF into cancer cells (4T1, PANC‐1, and HT29) as well as intestine epithelium cells (Caco‐2) is studied. The anti‐cancer effect of SRF is enhanced by up to fivefold in the presence of CAGE (0.5 mg mL−1). The effect is mediated not by enhancing the cellular uptake of SRF but by improving intracellular SRF retention by inhibiting exocytosis. Moreover, CAGE improves the anti‐tumor effect of SRF by increasing apoptosis and blocking cell‐cycle progression. Moreover, CAGE significantly enhances the penetration of SRF into and across multicellular constructs with multiple mechanisms involved. Collectively, the administration of ILs such as CAGE combined with SRF may offer a novel therapy to better inhibit tumor progression.
- 17 November 2020
- Published by Wiley in Advanced Healthcare Materials
- Vol. 10 (2) , e2001455
Enhancement of Anticancer Efficacy and Tumor Penetration of Sorafenib by Ionic Liquids
Ionic liquids (ILs) possess unique solvation and biological properties for drug delivery. Choline and geranic acid (CAGE) in particular, has been successfully formulated to orally deliver insulin and hydrophobic therapeutics such as sorafenib (SRF). However, relatively little is known about the effect of CAGE on intracellular delivery of drugs. Here the effect of low‐concentration CAGE (−1) on the delivery of SRF into cancer cells (4T1, PANC‐1, and HT29) as well as intestine epithelium cells (Caco‐2) is studied. The anti‐cancer effect of SRF is enhanced by up to fivefold in the presence of CAGE (0.5 mg mL−1). The effect is mediated not by enhancing the cellular uptake of SRF but by improving intracellular SRF retention by inhibiting exocytosis. Moreover, CAGE improves the anti‐tumor effect of SRF by increasing apoptosis and blocking cell‐cycle progression. Moreover, CAGE significantly enhances the penetration of SRF into and across multicellular constructs with multiple mechanisms involved. Collectively, the administration of ILs such as CAGE combined with SRF may offer a novel therapy to better inhibit tumor progression.